Annual Neuroimmunology and Multiple Sclerosis Clinical and Research Hybrid Program

Friday, December 20, 2024, 12:00 PM - 6:00 PM, Other, Worcester, MA


AMA PRA Category 1 Credits™ (4.50 hours), Contact Hours (MA Board of Nursing) (5.40 hours), Non-Physician Attendance (4.50 hours)

The diagnosis and treatment of Multiple Sclerosis (MS) continues to evolve with the recent announcement of a new iteration of McDonald criteria at the ECTRIMS congress in September 2024. The McDonald committee aimed to increase diagnostic specificity though a focus on the underlying biology of MS and have incorporated new imaging and fluid biomarkers with these goals in mind.

Additionally, there is a clear ongoing need for fluid and imaging biomarkers to identify, prognosticate, and respond to progressive (“smoldering”) MS biology. Progressive MS is more akin to a neurodegenerative condition, requiring a multifactorial approach to treatment. Unfortunately, there are no proven treatments to effectively address this problem in MS.

This UMass Chan Medical School Neuroimmunology/MS CME program covers the latest information on clinical and translational research on different clinical entities, treatments, and mechanisms of autoimmune demyelination involving the central nervous system.  The program will focus on the integration of data published in the literature and our own research collaborative work over the last year, with a 2024 focus on new biomarkers in MS.

1. Recognize and incorporate new elements of the 2024 McDonald criteria and MOGAD diagnostic criteria into their clinical practice
2. Interpret, summarize, and potentially translate findings from neurofilament light and glial fibrillary acidic protein research into clinical practice
3. Describe emerging areas of neuroinflammatory biology through use of imaging, proteomics, and basic research

Active UMass Department of Neurology Employee, Neurology Residents, Fellows & Students - Free
All Other Health Professionals - $300
Physicians or nurses not affiliated with UMass - $200
UMass Alumnus - $50 

 

UMass Chan Medical School is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The UMass Chan designates this live activity for a maximum of 4. 5 AMA PRA Category 1 Credits™.  Physicians should claim only credit commensurate with the extent of their participation in the activity.

Nurses: This program meets the requirements for 5.4 contact hours for nurses as specified by the Massachusetts Board of Registration in nursing (244-CMR 5.04). 

Others: Other healthcare professionals will receive a certificate that states this activity was designated for 4.5 AMA PRA Category 1 Credits™

Cancellation Policy

If you cancel your registration before November 25th, 2024 fee is refundable less a processing charge of $75. After that date, no refund will be given for any reason, including weather and other emergencies, substitutions are always welcome. UMass Chan Office of Continuing Medical Education and the Department of Neurology reserves the right to cancel a program at any time caused by circumstances not under its control.  Persons registered in a canceled program will be notified by email, using the email address provided when registering for the program.  There may also be changes in the program content caused by circumstances beyond the control of the Office of Continuing Medical Education.


Accessibility Statement
 
University of Massachusetts Chan Medical School is committed to ensuring that its programs, services, goods and facilities are accessible to individuals with disabilities as specified under Section 504 of the Rehabilitation Act of 1973 and the Americans with Disabilities Amendments Act of 2008.  If you have needs that require special accommodations, including dietary concerns, please contact the CME Conference Coordinator.

Beechwood Hotel
 363 Plantation St. Worcester, MA

Phone: 508-444-5850
Website

 

Disclosure Declarations
As a provider accredited by the ACCME, The University of Massachusetts Chan Medical School asks everyone in a position to control the content of an education activity to disclose all financial relationships with any ineligible companies. This includes any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if a financial relationship, in any amount, exists between the person in control of content and an ineligible company during the past 24 months, and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. 

Mitigation of Relevant Financial Relationships

All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Supported by sponsorship from:

- Genentech, a member of the Roche Group.

- Biogen

- EMD Serono, Inc. 

- Novartis Pharmaceuticals Corp.

- TG Therapeutics

- Pfizer